Skip to search formSkip to main contentSkip to account menu

SPD754

Known as: AVX-754, AVX754, SPD 754 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

apricitabine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2007
Review
2007
Apricitabine: A Novel Deoxycytidine Analogue Nucleoside Reverse Transcriptase Inhibitor for the Treatment of Nucleoside-Resistant HIV Infection
Existing nucleoside reverse transcriptase inhibitors for HIV disease are limited by problems of resistance and, in some cases… 
2006
2006
In Vitro Antiretroviral Activity and In Vitro Toxicity Profile of SPD754, a New Deoxycytidine Nucleoside Reverse Transcriptase Inhibitor for Treatment of Human Immunodeficiency Virus Infection
ABSTRACT SPD754 (AVX754) is a deoxycytidine analogue nucleotide reverse transcriptase inhibitor (NRTI) in clinical development… 
2006
2006
Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients
Objective:Apricitabine (formerly AVX754 and SPD754) is a deoxycytidine analogue nucleoside reverse transcriptase inhibitor in… 
2005
2005
In Vitro Activity of SPD754, a New Deoxycytidine Nucleoside Reverse Transcriptase Inhibitor (NRTI), against 215 HIV-1 Isolates Resistant to Other NRTIs
SPD754 (also known as AVX-754) is a deoxycytidine analogue nucleoside reverse transcriptase inhibitor (NRTI) with antiretroviral… 
2004
2004
New HIV Drug Class : ‘ Entry Inhibitors ’ Which Block HIV from Entering CD 4 Cell
IN THIS ISSUE: Tipranavir . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1 HIV Entry Inhibitors… 
Review
2004
Review
2004
New antiretroviral agents for the treatment of HIV infection
Issues, such as complexity, tolerability, and drug resistance and cross-resistance, limit the effectiveness of current… 
2004
2004
New antiretroviral agents for the treatment of HIV infection
Issues, such as complexity, tolerability, and drug resistance and cross-resistance, limit the effectiveness of current… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)